Compare Under Armour Inc Class A (UA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Under Armour Inc Class A vs Vertex Pharmaceuticals Incorporated — how do they compare? Under Armour Inc Class A trades at $4.79 (market cap $2.15B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 62.4× Under Armour Inc Class A's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| UA | VRTX | |
|---|---|---|
Market Cap | $2.15B | $134.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.88 | $557.96 |
52-Week Low | $3.96 | $376.62 |
Enterprise Value | $3.13B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Under Armour (UA) trades at $4.95, down 3.32% amid bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -9.99% and declining revenue trends. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. Cash flow remains negative, and the company faces challenges from softer consumer demand in key markets.
The outlook is cautious due to persistent revenue declines and negative margins. While analyst consensus leans slightly bullish with 40.3% buy ratings, significant risks include execution challenges and competitive pressures. Investors should weigh the potential for a turnaround against ongoing operational headwinds.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
